查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
心血管和軟組織修復貼片市場——增長、趨勢、COVID-19 影響和預測 (2023-2028)
市場調查報告書
商品編碼
1190228

心血管和軟組織修復貼片市場——增長、趨勢、COVID-19 影響和預測 (2023-2028)

Cardiovascular and Soft Tissue Repair Patches Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

心血管和軟組織修復貼片市場預計在預測期內的複合年增長率為 8%。

COVID-19 大流行的早期階段對市場產生了重大影響，因為嚴格的封鎖和政府限制減緩了 COVID-19 的傳播。 結果，臨床程序的數量減少了。 在大流行期間，由於封鎖規定，人們沒有去醫院和診所接受心血管護理。 根據 2021 年 5 月發表在 PubMed 上的一篇文章，在英國進行的一項研究發現，在 COVID-19 大流行期間，英格蘭各地的心臟手術數量顯著下降，超過 45,000 例手術出現赤字。研究表明，大多數心臟手術不是在大流行期間進行的，這可能會影響長期的發病率和死亡率。 根據 2022 年 3 月發表在 PubMed Central 上的一篇論文，美國的一項研究表明，在大流行期間，成年人的心臟手術量顯著減少。 而且，根據 2021 年 9 月在 PubMed Central 上發表的一篇論文，在大流行後重新開放期間觀察到住院和心血管手術未完全恢復到激增前的水平，但最終 COVID-19-預計將恢復到或超過 19 歲之前的水平。 因此，COVID-19 爆發對其前身的市場增長產生了負面影響。 目前，隨著大流行的消退，市場正在獲得牽引力，預計在本研究的預測期內將穩定增長。

此外，技術進步、先天性心髒病患病率增加以及研發支出增加是推動市場增長的因素。 此外，先天性心房和室間隔缺損患病率的上升以及微創手術的上升趨勢也導致貼片的廣泛採用，引發了市場增長。 此外，先天性膈疝和腹股溝疝的日益流行也推動了市場增長，因為這些貼片用於通過組織修復程序治療這些疾病。 NCBI 2022 年 8 月的數據表明，腹股溝疝會影響大約 25% 的男性和不到 2% 的女性，其中男性約佔腹股溝疝病例的 90%。 預計腹股溝疝患病率的增加將導致軟組織修復貼片的使用增加。 此外，製造商和研究機構之間加強合作、政府與心臟治療相關的舉措以及新技術的開發是推動心血管和軟組織修復貼片市場增長的其他因素。 然而，嚴格的監管框架可能會阻礙市場增長。

主要市場趨勢

推測軟組織修復部分未來會健康成長。

由於各種疝氣的患病率不斷上升，軟組織修復被認為代表了未來的健康成長。 疝氣是一種腸道或脂肪組織從腹部的薄弱部位突出的疾病。 軟組織修復補丁有助於治療疝氣疾病。 根據 PubMed 於 2022 年 4 月發表的一篇論文，埃塞俄比亞的一項研究表明外翻疝的總體患病率很高。 年齡大、便秘、長期咳嗽、提重物是導致疝氣外翻的主要原因。 此外，根據 PubMed Central 於 2021 年 8 月發表的一篇論文，在沙特阿拉伯對 500 名參與者進行的橫斷面研究中，18-25 歲的參與者中腹疝的患病率為 38.8%。患病率為21.2%。

市場主要參與者的重大發展對該細分市場的增長產生了積極影響。 例如，2021 年 7 月，全球醫療技術巨頭 BD（Becton, Dickinson and Company）宣布收購 Tepha, Inc.，以推進軟組織修復和再生方面的新創新。

因此，由於上述因素，預計軟組織修復領域在預測期內將出現顯著增長。

北美主導著心血管和軟組織修復市場

由於心髒病患病率上升、大量製藥公司的存在、研發支出增加以及疝病發病率增加，北美是全球心血管和軟組織修復補片市場中的一個大市場。預計一份。 例如，根據美國疾病控制與預防中心 2022 年 7 月的數據，心髒病是美國的主要死因之一。 據說在美國每34秒就有一個人死亡。 冠心病是最常見的心髒病，在美國影響著大約 2010 萬 20 歲及以上的成年人。

大量產品發布、市場參與者高度集中以及製造商在美國的存在是推動該國脫毛設備市場增長的一些因素。 例如，2020年2月，總部位於奧克蘭的私營軟組織修復公司Aroa Biosurgery在美國市場推出了一款用於軟組織修復和重建的新產品Myriad。 預計在該地區持續推出此類產品將推動該國的市場增長。

因此，由於上述因素，北美市場有望擴大。

競爭格局

心血管和軟組織修復貼片市場競爭適中，由幾家大型企業組成。 目前主導市場的公司包括 Anteris、LeMaitre Vascular Inc.、Baxter、Cryolife, Inc、CorMatrix, Inc、Abbott (St Jude Medical)、B. Braun Melsungen AG、Terumo Medical Corporation、Integra LifeSciences Corporation、Glycar，例如，SA Pty有限公司

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 調查先決條件
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 技術進步
    • 先天性心髒病增加
    • 研發費用增加
  • 市場製約因素
    • 監管框架
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 按原材料
    • 生物材料和組織工程材料
    • 膨體聚四氟乙烯
    • 其他
  • 通過使用
    • 心臟修復
    • 軟組織修復
    • 血管修復和重建
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Anteris
    • LeMaitre Vascular Inc.
    • Baxter
    • Cryolife, Inc.
    • CorMatrix, Inc
    • Abbott（St Jude Medical）
    • B. Braun Melsungen AG
    • Terumo Medical Corporation
    • Integra LifeSciences Corporation
    • Glycar SA Pty Ltd.

第7章 市場機會今後動向

簡介目錄
Product Code: 69708

The Cardiovascular and Soft Tissue Repair Patches Market is expected to register a CAGR of 8% during the forecast period.

The early phase of the COVID-19 pandemic significantly impacted the market, as the strict lockdowns and government regulations slowed the spread of COVID-19. This resulted in a reduction in the number of clinical procedures. During the pandemic, people did not visit hospitals or clinics for cardiovascular procedures due to lockdown restrictions. According to an article published by PubMed in May 2021, a study performed in United Kingdom showed that the number of cardiac procedures has significantly declined across England during the COVID-19 pandemic, with a deficit of more than 45,000 procedures, without an increase in the risk of mortality for most cardiac procedures were not performed during the pandemic, and this might impact long-term morbidity and mortality. Also, according to an article published by PubMed Central in March 2022, a study in United States showed that the adult cardiac surgery volume decreased significantly during the pandemic. And, according to an article published by PubMed Central in September 2021, in the reopening phase after the pandemic an incomplete recovery to pre-surge levels of hospitalizations and cardiovascular procedures was observed, but it is expected to eventually rebound to meet or exceed pre-COVID-19 levels. Thus, the COVID-19 outbreak affected the market's growth adversely in its preliminary phase; currently, the market has gained traction as the pandemic has subsided, and it is expected to have a stable growth during the forecast period of the study.

Further, the increasing technological advancements, increasing prevalence of congenital heart diseases, and increasing R&D expenditure attribute to the growth of the market. In addition, the rising prevalence of congenital atrial and ventricular septal defects and growing inclination towards minimally invasive procedures also result in high adoption of the patches and trigger the growth of the market. Moreover, an increase in the prevalence of congenital diaphragmatic hernias, and inguinal hernias is also promoting the growth of the market as these patches are used in the treatment of these disorders through tissue repairing procedures. As per the data by NCBI in August 2022, inguinal hernia affects nearly 25% of men and less than 2% of women over their lifetime, and males account for about 90% of all inguinal hernia cases. The increasing prevalence of inguinal hernia is expected to increase the usage of soft tissue repair patches. Furthermore, increasing collaboration between manufacturers and research organizations, government initiatives associated with cardiac treatments, and the development of novel technologies are a few more factors driving the growth of the cardiovascular and soft tissue repair patches market. However, the stringent regulatory framework is likely to impede market growth.

Key Market Trends

Soft Tissue Repair Segment is Estimated to Witness a Healthy Growth in Future.

Soft tissue repair is estimated to witness healthy growth in the future, attributed to the increasing prevalence of various types of hernias. A hernia is a disorder in which the intestine or fatty tissue protrudes through a weaker portion of the abdomen. Soft tissue repair patches help in treating hernia disorder. According to an article published by PubMed in April 2022, a study in Ethiopia showed that the overall prevalence of external hernia was high in the country. Old age, constipation, chronic cough, and lifting heavy objects were some major reasons behind external hernias. Furthermore, according to the article published by PubMed Central in August 2021, a cross-sectional study was performed on 500 participants in Saudi Arabia, which showed that the prevalence of abdominal hernia was 38.8 percent and the participants in 18-25 years had less prevalence of 21.2 percent.

Key developments by major players in the market are positively affecting the growth of the segment. For instance, in July 2021, BD (Becton, Dickinson and Company), a leading global medical technology company, announced that they had acquired Tepha, Inc., to drive new innovations in soft tissue repair and generation.

Therefore, the soft tissue repair segment is expected to witness significant growth over the forecast period due to the abovementioned factors.

North America is Dominating the Cardiovascular and Soft Tissues Repair Market

North America is expected to hold a significant market share in the global Cardiovascular and Soft Tissue Repair Patches Market due to the rising prevalence of cardiac diseases, the presence of a large number of pharmaceutical companies, growing research and development expenditure, and increasing incidences of hernia disorders. For instance, according to data from the Centers for Disease Control and Prevention in July 2022, heart disease is one of the leading causes of death in United States. It is estimated that one person dies every 34 seconds in United States. Among all the heart diseases coronary heart disease is the most common type of heart disease and about 20.1 million adults age 20 and older have coronary heart disease in United States.

Key product launches, high concentration of market players, and manufacturers' presence in United States are some of the factors driving the growth of the hair removal devices market in the country. For instance, in February 2020, Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, launched Myriad, a new product for soft tissue repair and reconstruction, in United States market. These continuous product launches in the region are anticipated to drive the growth of the market in the country.

Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North American region.

Competitive Landscape

The Cardiovascular and Soft Tissue Repair Patches Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Anteris, LeMaitre Vascular Inc., Baxter, Cryolife, Inc., CorMatrix, Inc, Abbott (St Jude Medical), B. Braun Melsungen AG, Terumo Medical Corporation, Integra LifeSciences Corporation, and Glycar SA Pty Ltd among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements
    • 4.2.2 Increasing Prevalence of Congenital Heart Diseases
    • 4.2.3 Increasing R&D Expenditure
  • 4.3 Market Restraints
    • 4.3.1 Regulatory Framework
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Raw Material
    • 5.1.1 Biomaterial and Tissue Engineered Material
    • 5.1.2 ePTFE
    • 5.1.3 Others
  • 5.2 By Application
    • 5.2.1 Cardiac Repair
    • 5.2.2 Soft Tissue Repair
    • 5.2.3 Vascular Repair & Reconstruction
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Anteris
    • 6.1.2 LeMaitre Vascular Inc.
    • 6.1.3 Baxter
    • 6.1.4 Cryolife, Inc.
    • 6.1.5 CorMatrix, Inc
    • 6.1.6 Abbott (St Jude Medical)
    • 6.1.7 B. Braun Melsungen AG
    • 6.1.8 Terumo Medical Corporation
    • 6.1.9 Integra LifeSciences Corporation
    • 6.1.10 Glycar SA Pty Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS